MedTrace Logo

Myopia:the Role of Cone Opsin Mutations & Glasses That Control Axial Elongation

NCT01923675 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2019-08-14

No results posted yet for this study

Summary

1. To determine the effect of spectacles with a red blocking filter on myopia progression in children.
2. To determine the effect of spectacles with a holographic diffuser that spreads incident light rays over an angle of 0.5 degrees on myopia progression in children
3. To determine the combined effects of spectacles with a red blocking filter and a diffuser that spreads incident light over an angle of 0.5 degrees on myopia progression in children.

Conditions

  • Myopia

Interventions

OTHER

Spectacles with red-blocking tint

Eyeglasses will have lenses that will correct refractive error for each subject, and will have a tint that blocks red light.

OTHER

Spectacles with holographic diffuser and color neutral tint

Eyeglasses will correct refractive error for each subject but will have a holographic diffuser applied to the surface and will have a color neutral filter to adjust the light intensity reaching the eyes to be the same as for groups 1 and3.

OTHER

Spectacles with holographic diffuser and red-blocking tint

Eyeglasses will correct refractive error for each subject and will be tinted to block red light, and will have a holographic diffuser to blur the image.

OTHER

Spectacles with color neutral tint

Eyeglasses will correct refractive error for each subject and will have a color neutral tint to adjust the light intensity reaching the eyes so it is the same as for groups 1 and 3.

Sponsors & Collaborators

Principal Investigators

  • Jay Neitz, PhD · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
13 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01923675 on ClinicalTrials.gov